基于[18F]FDG PET/CT预测接受伊匹木单抗联合纳武利尤单抗±UV1端粒酶疫苗治疗的胸膜间皮瘤患者结局
本研究基于NIPU试验中接受伊匹木单抗联合纳武利尤单抗±端粒酶疫苗二线治疗的胸膜间皮瘤患者,在基线和第5周行[18F]FDG PET/CT,评估MTV和SUVpeak与生存结局的关系。单因素Cox回归显示MTV与OS(HR 1.36)和PFS(HR 1.18)显著相关,多因素分析中MTV仅与OS显著相关(HR 1.35),SUVpeak在多因素分析中与OS显著相关(HR 0.43)。客观缓解者第5周TLG、SUVmax和SUVpeak显著下降。
要点
- MTV与胸膜间皮瘤免疫治疗后的OS和PFS显著相关
- 高SUVpeak与更差结局无关,多因素分析中SUVpeak与OS显著相关(HR 0.43)
核心结论
- MTV在胸膜间皮瘤免疫治疗中具有预后价值
- 高SUVpeak与更差结局无关,可能归因于免疫治疗的独特机制
- PET指标的早期下降与治疗缓解相关
研究设计与样本
- 来自NIPU试验(NCT04300244)的患者,接受伊匹木单抗联合纳武利尤单抗±端粒酶疫苗二线治疗
- 基线行[18F]FDG PET/CT者n=100,第5周行[18F]FDG PET/CT者n=76
- 评估MTV和SUVpeak与生存结局的关系
- 采用Wilcoxon秩和检验比较客观缓解者(按mRECIST和iRECIST定义为部分缓解或完全缓解)与非缓解者(最佳总体疗效为疾病稳定或疾病进展)之间MTV、TLG、SUVmax和SUVpeak的差异
主要发现
- 客观缓解者第5周TLG、SUVmax和SUVpeak显著下降
关键数值与推荐
- 客观缓解按mRECIST和iRECIST定义为部分缓解或完全缓解
- 非缓解者定义为最佳总体疗效为疾病稳定或疾病进展
临床怎么用
- 原文未据此给出推荐
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study explores the role of [18F]FDG PET/CT in predicting outcomes in PM treated with immunotherapy. METHODS: Patients from the NIPU trial, receiving ipilimumab and nivolumab +/- telomerase vaccine in second-line, were included. [18F]FDG PET/CT was obtained at baseline (n = 100) and at week-5 (n = 76). Metabolic tumour volume (MTV) and peak standardised uptake value (SUVpeak) were evaluated in relation to survival outcomes. Wilcoxon rank-sum test was used to assess differences in MTV, total lesion glycolysis (TLG), maximum standardised uptake value (SUVmax) and SUVpeak between patients exhibiting an objective response, defined as either partial response or complete response according to the modified Response Criteria in Solid Tumours (mRECIST) and immune RECIST (iRECIST), and non-responders, defined as either stable disease or progressive disease as their best overall response. RESULTS: Univariate Cox regression revealed significant associations of MTV with OS (HR 1.36, CI: 1.14, 1.62, p < 0.001) and PFS (HR 1.18, CI: 1.03, 1.34, p = 0.02), while multivariate analysis showed a significant association with OS only (HR 1.35, CI: 1.09, 1.68, p = 0.007). While SUVpeak was not significantly associated with OS or PFS in univariate analyses, it was significantly associated with OS in multivariate analysis (HR 0.43, CI: 0.23, 0.80, p = 0.008). Objective responders had significant reductions in TLG, SUVmax and SUVpeak at week-5. CONCLUSION: MTV provides prognostic value in PM treated with immunotherapy. High SUVpeak was not associated with inferior outcomes, which could be attributed to the distinct mechanisms of immunotherapy. Early reductions in PET metrics correlated with treatment response. STUDY REGISTRATION: The NIPU trial (NCT04300244) is registered at clinicaltrials.gov. https://classic. CLINICALTRIALS: gov/ct2/show/NCT04300244?cond=Pleural+Mesothelioma&cntry=NO&draw=2&rank=4.
引用
- Thunold S, Hernes E, Farooqi S, et al. Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. Eur J Nucl Med Mol Imaging. 2024. PMID: 39133306. doi:10.1007/s00259-024-06853-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。